Cisplatin resistance in lung cancer is mediated by MACC1 expression through PI3K/AKT signaling pathway activation

查看全文 作　　者：Qiang [1,2,3,4]Zhang;Bin [1,2,3,4]Zhang;Leina [2,3,4,5]Sun;Qingna [2,3,4,5]Yan;Yu [1,2,3,4]Zhang;Zhenfa [1,2,3,4]Zhang;Yanjun [1,2,3,4]Su;Changli [1,2,3,4]Wang

机构地区：[1]Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin 300060, China;[2]Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China;[3]Tianjin Lung Cancer Center, Tianjin 300060, China;[4]Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China;[5]Department of Pathology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China

出　　处：《Acta Biochimica et Biophysica Sinica》索引2018年第50卷第8期,共9页

基　　金：This work was supported by the grants from the Nationa Key Research and Development Program of China (Nos 2016YFC0905501 and 2016YFC0905500) and the Nationa Natural Science Foundation of China (No. 81772484). 关键词：小径癌症 apoptosis 激活肺联合治疗 mRNA VIVO

相关文献

参考文献（34）
引证文献（4）
耦合文献（0）

参考文献(34)

引证文献(4)

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

Cisplatin resistance in lung cancer is mediated by MACC1 expression through PI3K/AKT signaling pathway activation

参考文献(34)

引证文献(4)

用户提示